Kee‐Sik Kim

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Milton Packer, John J.V. McMurray, Akshay S. Desai et al. · Circulation · 2014 · 667 citations · Full text

Medicine, Cardiology, Pharmacology +16

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress

Jang‐Ho Bae, E. Bassenge, Yoon-Nyun Kim et al. · Atherosclerosis · 2001 · 371 citations · Full text

Life Sciences, Nutritional Sciences, Physiology +14

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Cheol Whan Lee, Jung‐Min Ahn, Duk‐Woo Park et al. · Circulation · 2013 · 281 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17